For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Epimmune Inc.

USPTO Granted Patents = 17

% Expired Patents = 17.6

EPO Patents = 11

Forward Citations = 439

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Alessandro D Sette (13 out of 42 patents)

John Sidney (9 out of 17 patents)

Scott Southwood (9 out of 12 patents)

4. Robert W Chesnut (7 out of 15 patents)

5. Esteban Celis (7 out of 19 patents)

6. Howard M Grey (7 out of 16 patents)

7. Brian D Livingston (5 out of 11 patents)

8. Ralph T Kubo (4 out of 7 patents)

9. Mark Joseph Newman (4 out of 12 patents)

10. John D Fikes (3 out of 9 patents)

11. Jeffery L Alexander (3 out of 5 patents)

12. Maria A Vitiello (3 out of 4 patents)

13. Robert W Chestnut (2 out of 2 patents)

14. Lilia Maria Babe (1 out of 31 patents)

15. Yiyou Chen (1 out of 12 patents)

17 patents: Sort by Forward Citations

1. 9789181 - PAN-DR binding polypeptides and uses thereof (2017-10-17),

2. 9511134 - Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions (2016-12-06),

3. 9340577 - HLA binding motifs and peptides and their uses (2016-05-17),

4. 9266930 - [object Object] (2016-02-23),

5. 9249187 - Pan-DR binding polypeptides and uses thereof (2016-02-02),

6. 8017745 - [object Object] (2011-09-13),

7. 7888472 - Optimized multi-epitope constructs and uses thereof (2011-02-15),

8. 7026443 - Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions (2006-04-11),

9. 6689363 - Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions (2004-02-10),

10. 6602510 - HLA class I A2 tumor associated antigen peptides and vaccine compositions (2003-08-05),

11. 6534482 - Expression vectors for stimulating an immune response and methods of using the same (2003-03-18),

12. 6464980 - MAGE-1 c-terminal immunogenic peptides (2002-10-15),

13. 6419931 - Compositions and methods for eliciting CTL immunity (2002-07-16),

14. 6413935 - Induction of immune response against desired determinants (2002-07-02),

15. 6413517 - Identification of broadly reactive DR restricted epitopes (2002-07-02),

EPIMMUNE INC. is a biotechnology company focused on developing novel immunotherapies for the treatment of cancer and other diseases. With a mission to harness the power of the immune system, EPIMMUNE is conducting cutting-edge research and development to create innovative therapies that target and activate specific immune cells to fight against cancer cells. Through their proprietary technologies and strategic collaborations, EPIMMUNE aims to revolutionize cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

17 Patents

#339 in San Diego, CA

#4,505 in California

#18,865 in US

#35,857 in the World

San Diego, CA, United States of America

Epimmune Inc.

Forward Citations = 439

30 inventors:

Alessandro D Sette (13 out of 42 patents)

John Sidney (9 out of 17 patents)

Scott Southwood (9 out of 12 patents)

4. Robert W Chesnut (7 out of 15 patents)

5. Esteban Celis (7 out of 19 patents)

Please report any incorrect information to [email protected]

Loading…